✦ LIBER ✦

Phase II trial of aclacinomycin A in acute leukemia and various solid tumors

✍ Scribed by J. Schütte; N. Niederle; S. Seeber

Book ID: 112295470
Publisher: Springer-Verlag
Year: 1983
Tongue: English
Weight: 521 KB
Volume: 105
Category: Article
ISSN: 1432-1335
DOI: 10.1007/bf00406927

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of ICRF-187 in children w

Phase II trial of ICRF-187 in children with solid tumors and acute leukemia

✍ Tribhawan Vats; Barton Kamen; Jeffrey P. Krischer 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 280 KB

ICRF-187 is the ( + ) enantiomer of the racemic mixture razoxane . This compound is much more water soluble and thus could be formulated for parental use. The maximum tolerated dose in children after phase I trials was determined to be 3500 mg/MVday x 3 days. A phase II trial of ICRF-187 was done in

A phase II study of aclacinomycin A in a

A phase II study of aclacinomycin A in acute leukemia in adults

✍ Yamada, K.; Nakamura, T.; Tsuruo, T.; Kitahara, T.; Maekawa, T.; Uzaka, Y.; Kuri 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 516 KB

Preliminary results of a phase II trial

Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma

✍ G. Mathé; M. Bayssas; J. Gouveia; D. Dantchev; P. Ribaud; D. Machover; J. L. Mis 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 303 KB

Phase II trial of vincristine infusion i

Phase II trial of vincristine infusion in acute leukemia

✍ Don V. Jackson; Allen R. Chauvenet; Richard D. Callahan; James N. Atkins; Thomas 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 386 KB

Phase II trial of plicamycin and hydroxy

Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia

✍ Eric Archimbaud; Jacques Troncy; Catherine Sebban; Denis Guyotat; Yves Devaux; M 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 229 KB

Amsa: A phase II trial in resistant and

Amsa: A phase II trial in resistant and recurrent acute myelogenous leukemia

✍ Boccia, Ralph ;Zighelboim, Jacob ;Champlin, Richard E. ;Kim, Chun Choo ;Gale, Ro 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA. Three achieved a complete remission, and two a partial remission. Median survival for all patients was 12 weeks and was 16 weeks for responders